libri scuola books Fumetti ebook dvd top ten sconti 0 Carrello


Torna Indietro

smith paul j. (curatore); yue eddy w. (curatore) - inhibitors of cyclin-dependent kinases as anti-tumor agents
Zoom

Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents

;




Disponibilità: Normalmente disponibile in 20 giorni
A causa di problematiche nell'approvvigionamento legate alla Brexit sono possibili ritardi nelle consegne.


PREZZO
266,98 €
NICEPRICE
253,63 €
SCONTO
5%



Questo prodotto usufruisce delle SPEDIZIONI GRATIS
selezionando l'opzione Corriere Veloce in fase di ordine.


Pagabile anche con Carta della cultura giovani e del merito, 18App Bonus Cultura e Carta del Docente


Facebook Twitter Aggiungi commento


Spese Gratis

Dettagli

Genere:Libro
Lingua: Inglese
Editore:

CRC Press

Pubblicazione: 10/2006
Edizione: 1° edizione





Trama

One of the few books to cover all aspects of cyclin-dependent kinases (CDKs), this volume provides an overview of CDKs as molecular and functional entities, their involvement in different disease processes, and their potential for pharmacological modulation. The first two sections discuss the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors. The third section examines the design, development, and chemistry of small molecule CDK inhibitors. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future development of CDK inhibitors as anticancer agents.




Note Editore

One of the few books to cover all aspects of cyclin-dependent kinases (CDKs), Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents provides an overview of CDKs as molecular and functional entities, their involvement in different disease processes, and their potential for pharmacological modulation. With contributions from the top international researchers in the field, the book takes a contemporary approach to study the importance of rational drug design and knowledge-based therapeutics in relation to CDKs. The first two sections of the book discuss the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors, exploring topics such as the in vivo function of CDKs in normal homeostasisand tumor development and the structural biology of CDKs. The third section examines the design, development, and chemistry of small molecule CDK inhibitors, with discussions ranging from the early-stage discovery of new chemical entities with a capacity to inhibit CDKs to late-stage compounds in clinical development. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future development of CDK inhibitors as anticancer agents. The field of drug development is at a critical point in terms of understanding the availability, advantages, and drawbacks of CDKs as therapeutic targets for small molecules. Providing the most up-to-date, in-depth coverage available in a single volume, Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents surveys the success of the agents developed thus far, the possibility of new routes to more selective inhibitors, and the growing appreciation of critical, therapeutic issues.




Sommario

INTEGRATION OF CELL CYCLE CONTROL PATHWAYS AND THE OPPORTUNITIES FOR TARGETING Cell Cycle Dynamics and the Challenges for CDK Targeting Paul J. Smith, Emeline Furon, and Rachel J. Errington Functional Regulation of CIP/KIP CDK Inhibitors Mong-Hong Lee and Ruiying Zhao Mouse Models to Study the In Vivo Function of Cyclin-Dependent Kinases in Normal Homeostasis and Tumor Development Marcos Malumbres, Pierre Dubus, and Sagrario Ortega Cyclin-Dependent Kinase Inhibitors and Vascular Disease Martin F. Crook and Manfred Boehm CDK INHIBITORS: TARGETS AND THEIR EVALUATION Evaluation of CDK Inhibitor Selectivity: From Affinity Chromatography to Yeast Genetics Stéphane Bach, Marc Blondel, and Laurent Meijer Development of CDK Inhibitors as Anticancer Agents: From Rational Design to CDK4-Specific Inhibition Sachin Mahale and Bhabatosh Chaudhuri Three-Dimensional Structures of Cyclin-Dependent Kinases and Their Inhibitor Complexes Ursula Schulze-Gahmen and Sung-Hou Kim CDK INHIBITORS: CHEMISTRY FOCUS Cyclin-Dependent Kinase Small Molecule Modulators for Cancer Therapy Adrian M. Senderowicz (R)-Roscovitine (CYC202, Seliciclib) Laurent Meijer, Karima Bettayeb, and Hervé Galons Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors Conrad Kunick, Thomas Lemcke, and Laurent Meijer Discovery of BMS-387032, a Potent Cyclin-Dependent Kinase Inhibitor in Clinical Development John T. Hunt Oxindole Inhibitors of Cyclin-Dependent Kinases as Antitumor Agents Philip A. Harris Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors David J. Carini, Catherine R. Burton, and Steven P. Seitz Development of Indolocarbazoles as Cyclin D1/CDK4 Inhibitors Guoxin Zhu Pyrazoles as Efficient Adenine-Mimetic Heterocycles for the Discovery of CDK Inhibitors Paolo Pevarello and Anna Vulpetti Pyrazolo [3,4-d] pyrimidin-4-ones: Exploring the Structural Determinants of Potency and Selectivity in Cyclin-Dependent Kinase Inhibition Jay A. Markwalder and Steven P. Seitz THERAPEUTIC PERSPECTIVE Cyclin-Dependent Kinase Inhibitors and Combination Therapy: Experimental and Clinical Status Lloyd R. Kelland CDK Inhibitors as Anticancer Agents: Perspectives for the Future Jayalakshmi Sridhar, Nagarajan Pattabiraman, Eliot M. Rosen, and Richard G. Pestell INDEX










Altre Informazioni

ISBN:

9780849337741

Condizione: Nuovo
Collana: Enzyme Inhibitors Series
Dimensioni: 9.25 x 6.25 in Ø 1.75 lb
Formato: Copertina rigida
Illustration Notes:106 b/w images, 8 color images, 76 tables and 30 halftones
Pagine Arabe: 448


Dicono di noi